 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H32N22+ |
| Molar mass | 240.435 g·mol−1 |
| |
Pentolinium, also known aspentapyrrolidinium, is aganglionic blocking agent which acts as anicotinic acetylcholine receptorantagonist. Formulated as the pentolinium tartratesalt, it was marketed under the trade nameAnsolysen.[1] It can be used as anantihypertensive drug during surgery or to control hypertensive crises. It works by binding to theacetylcholinereceptor of adrenergic nerves and thereby inhibiting the release ofnoradrenaline andadrenaline. Blocking this receptor leads tosmooth muscle relaxation andvasodilation.
Pentolinium can be given orally (20mg three times a day), injectedintramuscularly, or administeredintravenously.[2]
Pentolinium andhexamethonium combined withRauvolfia was reported in 1955 to be effective in the outpatient management of moderate to severe hypertension, with satisfactory orthostatic reduction in blood pressure but there are significant untoward effects attributable to the use of the hexamethonium. Pentolinium has been reported to offer more prolonged ganglionic blockade and has less severe untoward effects than hexamethonium.[3]
Pentolinium was developed in the early 1950s atMay & Baker among several other related compounds with potential ganglionic blocking activity.[4] It was assigned the code nameM. & B. 2050A. The first clinical trials were conducted byF. H. Smirk atDunedin Hospital in 1952.[5][6]
